Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAF V600E mutation...
Editorial Commentary
Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAFV600E mutation with PD-L1 90%—a debate in a niche population